LogicMark, Inc.
LGMKAbout the company
LogicMark, Inc. provides personal emergency response systems (PERS), health communications devices, and Internet of Things (IoT) technology that creates a connected care platform in the United States. The company offers Guardian Alert 911 Plus, Freedom Alert, Freedom Alert Mini, and Freedom Alert Max, which are home-based landline solutions.
Investment snapshot
Positive
1
BUY / PASS
Neutral / negative
2 / 13
NEUTRAL / FAIL
Median fair value
—
No comparable estimates
Models with upside
0 / 17
Positive margin of safety
Key risk
No clean pass — all 13 investors flag at least one valuation criterion
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | Not ranked | PASS | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | NEUTRAL | FAIL | FAIL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Margin of Safety | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Annual history · FY 2025 Latest source filing: 2026-08-19 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-27 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 vs 2025-06-30 · TTM ended 2026-06-30 Latest source filing: 2026-08-19 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-27 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-27 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-10-01 Latest source filing: 2026-08-19 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-03-27 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-03-27 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-06-30 Latest source filing: 2026-08-19 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-27 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 · Market data at 2026-10-01 Latest source filing: 2026-08-19 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-10-01 Latest source filing: 2026-03-27 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-27 Score computed: 2026-11-14 | TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Price history 2025-01-01–2026-10-01 · Annual history · FY 2025 Latest source filing: 2026-08-19 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 Latest source filing: 2026-08-19 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-06-30 Latest source filing: 2026-08-19 Score computed: 2026-11-14 | TTM ended 2026-06-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-10-01 Latest source filing: 2026-08-19 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Valuation0% pass✓ 9✗ 19▾
No clean pass — all 13 investors flag at least one valuation criterion
Price / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio0.1x✓Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise ValueN/A (EV <= 0)✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=N/A (EV <= 0), ROC=-127.2%✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xPrice / Book Value per Share0.1x✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)Valuation ReasonablenessOE Yield=-466.8%✗MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldFCF Yield=-438.7%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical AverageP/B=0.1x✓MarksP/E < 15 or P/B < 2.0Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePrice / FCF per ShareN/A (negative FCF)✗Ackman<= 25Price vs. Trailing Low258% of trailing low ($0.50)✗Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization-532.37%; #5933/6340 (top 93.6%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization+11.2792; #179/6449 (top 2.8%)✓AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per Share0.09x✓SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+10.7243; #307/5247 (top 5.9%)✓OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization-349.78%; #4299/4519 (top 95.1%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date+157.94%; #195/6202 (top 3.1%)✓OshaughnessyTop 10% of eligible cross-section - Cash Flow0% pass✓ 1✗ 11▾
No clean pass — all 10 investors flag at least one cash flow criterion
Free Cash Flow Proxy$-5.5M✗BuffettPositive and growingFCF Positive and Growing$-5.1M✗LynchPositive and growingOperating Cash Flow$-5.1M✗PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=-24.92%, ROA=-36.77%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xP/E or FCF YieldFCF Yield=-438.7%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive0/4 years FCF positive✗MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap-347.3%✗Ackman>= 4%Price / FCF per ShareN/A (negative FCF)✗Ackman<= 25Positive Operating Cash Flow frequency1/13 years positive✗SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$-4.1M✗Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization-349.78%; #4299/4519 (top 95.1%)✗OshaughnessyTop 10% of eligible cross-section - Growth0% pass✓ 1✗ 12▾
No clean pass — all 8 investors flag at least one growth criterion
EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue GrowthInv: 51.1% vs Rev: 20.6%✗LynchInventory growth < Revenue growthEPS Growth Direction$-0.01 (2012) -> $-13.06 (2025)✗DremanPositive over recent yearsEPS CAGR✗Dreman> 5% annualizedPositive Net Income Frequency0/14 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth-0.3%✗Ackman>= 5%Positive EPS Growth Frequency2/5 years with positive EPS growth✗AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trendgross margin 67.1% -> 66.8%, operating margin -154.4% -> -69.1%✓SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR-0.0%✗SleepCAGR > 7%3-5 Year Diluted EPS CAGR✗Neff7%-20% annualized - Verdicts7% pass✓ 1✗ 13▾
Split decision: 13 FAIL · 2 NEUTRAL · 1 PASS
Overall verdict✗GrahamFAIL (2/9)✗BuffettFAIL (1/9)✗LynchFAIL (0/7)•GreenblattNot ranked✓PiotroskiPASS (F-Score 4)✗DremanFAIL (2/11)✗MungerFAIL (0/4)✗PabraiFAIL (1/3)✗AkreFAIL (1/6)✗MarksFAIL (1/5)✗AckmanFAIL (1/9)✗TempletonFAIL (3/8)✗SleepFAIL (2/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (0/6)✗SchlossFAIL (3/7)•OshaughnessyNEUTRAL (Not ranked) - Debt & Leverage8% pass✓ 3✗ 12▾
11 of 12 flag LGMK's debt & leverage — Graham, Buffett, Lynch +8 more
LT Debt vs Net Current Assets✗GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest Coverage✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / Equity✗Lynch< 0.33Cash - Long-term Debt✗LynchPositive preferredLT Debt / Total Assets Change0.00% -> 0.00%✓PiotroskiDecreased YoYCurrent Assets / Current Liabilities4.88✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00xDebt Levels✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDA✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity✗Ackman<= 1.0Negative debt-to-equity (higher means less debt)✗AsnessTop 30% of eligible cross-section - Profitability13% pass✓ 7✗ 28▾
14 of 16 flag LGMK's profitability — Graham, Buffett, Lynch +11 more
Positive EPS (10 years)0/15 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)✗Graham>= 33% growthNet Income Positive (10+ years)0/15 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)-64.1%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)-69.1% (latest)✓BuffettStable or rising over 10 yearsFree Cash Flow Proxy$-5.5M✗BuffettPositive and growingEarnings Variance (10-yr CoV)N/A (negative mean EPS)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROE-47.2%✗Lynch> 15%EBIT / Enterprise ValueN/A (EV <= 0)✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=N/A (EV <= 0), ROC=-127.2%✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets-36.77%✗PiotroskiROA > 0ROA Change YoY-63.31% -> -36.77% (delta: +26.54%)✓PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=-24.92%, ROA=-36.77%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY66.8% -> 66.8%✗PiotroskiImproved YoYPre-Tax Income / Revenue-49.5%✗Dreman>= 8%Net Income / Shareholders' Equity-47.2%✗Dreman> 12%Margin of SafetyP/B=0.1x✓PabraiP/B < 1.5 or P/E < 15Return on Equity-81.2% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePositive Net Income Frequency0/14 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue-51.9%✗Ackman>= 15%Net Income / Shareholders Equity-47.2%✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend-154.4% (2023) -> -69.1% (2025)✓TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trendgross margin 67.1% -> 66.8%, operating margin -154.4% -> -69.1%✓SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization-532.37%; #5933/6340 (top 93.6%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets+50.86%; #653/3702 (top 17.6%)✓AsnessTop 30% of eligible cross-sectionNet income / positive book equity-47.20%; #4175/5226 (top 79.9%)✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-0.2128; #4291/5884 (top 72.9%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR✗Neff7%-20% annualizedPositive Diluted-EPS Years0/10 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Efficiency25% pass✓ 3✗ 8▾
6 of 8 flag LGMK's efficiency — Buffett, Greenblatt, Piotroski +3 more
Current Ratio4.88✓Graham>= 2.0ROIC (3-5 yr avg)-103.1%✗Buffett> 10%ROIC - WACC-113.1%✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)-127.2%✗Greenblatt> 25%Current Ratio Change YoY2.63 -> 6.00✓PiotroskiIncreased YoYRevenue / Total Assets Change YoY0.70x -> 0.56x✗PiotroskiImproved YoYCurrent Assets / Current Liabilities4.88✓Dreman> 1.5Return on Invested Capital✗Munger> 15%ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROIC✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)✗SleepROIC > 12% in a majority of years
Business & financials
Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2025
Issued 42.7% of shares last year, 57.9% over two.
- Buybacks
- —
- Dividends
- —
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.
| Metric | TTM · 2026-06-30 2025-07-01 – 2026-06-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, capex, revenue, net income, operating income, gross profit, ebit, pre tax income, depreciation amortization. | Q2 FY 2026 2026-04-01 – 2026-06-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, capex. | Q1 FY 2026 2026-01-01 – 2026-03-31 Sources | FY 2025Sources
| FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
|
|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.2Mcurrent | -- | -- | $616.1Kest. | $547.7Mest. | $41.9Best. | $864.8Best. | $9.5Test. |
| Revenue | $12.5M↑21% | $3.3M↑17% | $3.2M↑24% | $11.4M↑15% | $9.9M | $9.9M↓17% | $11.9M↑19% | $10.0M |
| Operating Income | -$6.5M↑22% | -$1.6M↑25% | -$1.5M↑36% | -$7.9M↓3% | -$7.7M↑50% | -$15.3M↓122% | -$6.9M↑8% | -$7.5M |
| Net Income | -$6.2M↑34% | -$1.6M↑24% | -$1.5M↑34% | -$7.5M↑17% | -$9.0M↑38% | -$14.6M↓110% | -$6.9M↑41% | -$11.7M |
| EPS (Diluted) | -- | $-1.81 | $-1.68↓1300% | $-13.06↑11% | $-14.65↓26% | $-11.66↓1434% | $-0.76↑66% | $-2.23 |
| Gross Margin | 69.1%↑5% | 70.7%↑5% | 69.6%↑10% | 66.8% | 66.8% | 67.1%↑11% | 60.7%↑5% | 57.7% |
| Operating Margin | -51.9%↑35% | -47.6%↑36% | -46.8%↑49% | -69.1%↑11% | -77.5%↑50% | -154.4%↓166% | -58.0%↑23% | -75.3% |
| ROE | -47.2%↑3% | — | — | -45.9%↑47% | -86.7%↑22% | -111.0%↓236% | -33.0%↑25% | -44.0% |
| Total Debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Shareholders' Equity | $13.2M↓32% | $13.2M↓32% | $14.8M↓30% | $16.3M↑57% | $10.4M↓21% | $13.1M↓38% | $21.0M↓21% | $26.6M |
| Current Ratio | 4.88↓35% | 4.88↓35% | 6.30↓17% | 6.00↑128% | 2.63↓33% | 3.92↓1% | 3.95↓63% | 10.76 |
| Debt / Equity | — | — | — | — | — | — | — | — |
| Operating Cash Flow | -$4.0M↑8% | $83.3K↑108% | -$1.6M | -$5.1M↓19% | -$4.3M↑1% | -$4.3M↓20% | -$3.6M↑39% | -$5.9M |
| Free Cash Flow | -$4.1M | $48.2K | -$1.7M | -$5.1M↓20% | -$4.3M↑2% | -$4.4M↓12% | -$3.9M | -- |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Medical Equipment
LGMK vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALCON INCALC | $35.6B | $74.12 | $10.4B | $980.0M | 4.4% | 0.21 | 13.1% | 2.12 | 2/9 | 1/9 | 3/7 | 0/3 | F-Score 6 | 4/11 |
| KONINKLIJKE PHILIPS NVPHG | $29.7B | $30.34 | $21.0B | $1.1B | 8.2% | 0.64 | 8.0% | 1.32 | 1/9 | 1/9 | 1/7 | 0/3 | F-Score 5 | 3/11 |
| WEST PHARMACEUTICAL SERVICES INCWST | $29.0B | $416.42 | $3.1B | $493.7M | 15.5% | 0.06 | 19.0% | 3.02 | 4/9 | 6/9 | 6/7 | 1/3 | F-Score 7 | 5/11 |
| SMITH & NEPHEW PLCSNN | $13.1B | $31.28 | $6.2B | $625.0M | 11.8% | 0.59 | 12.9% | 2.57 | 2/9 | 0/9 | 1/7 | 0/3 | F-Score 6 | 4/11 |
| MSA Safety IncMSA | $6.7B | $174.17 | $1.9B | $278.9M | 20.4% | 0.42 | 19.8% | 3.01 | 5/9 | 5/9 | 4/7 | 1/3 | F-Score 5 | 7/11 |
| STAAR SURGICAL COSTAA | $1.3B | $26.39 | $239.4M | $80.4M | -23.4% | — | -38.3% | 4.55 | 2/9 | 2/9 | 2/7 | 0/3 | F-Score 3 | 3/11 |
| ARTIVION, INC.AORT | $931.9M | $19.10 | $441.3M | $9.8M | 2.2% | 0.48 | 7.6% | 3.53 | 2/9 | 0/9 | 0/7 | 0/3 | F-Score 7 | 1/11 |
| InMode Ltd.INMD | $763.6M | $13.27 | $370.5M | $93.8M | 13.7% | — | 23.0% | 9.88 | 5/9 | 3/9 | 0/7 | 3/3 | F-Score 4 | 4/11 |